1. Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients.
- Author
-
Bordat, Claire, Cuerq, Charlotte, Halimi, Charlotte, Vairo, Donato, Blond, Emilie, Restier, Liora, Poinsot, Pierre, Duclaux-Loras, Rémi, Peretti, Noël, and Reboul, Emmanuelle
- Subjects
VITAMIN therapy ,BIOLOGICAL models ,IN vitro studies ,LIPID metabolism disorders ,CAROTENOIDS ,VISION ,LIPOPROTEINS ,DESCRIPTIVE statistics ,CELL lines ,BETA carotene ,LUTEIN ,GENETIC disorders ,ZEAXANTHIN ,MALABSORPTION syndromes ,GENETIC mutation ,DIETARY supplements - Abstract
• Hypobetalipoproteinemia disorders are characterized by lipid malabsorption. • There is no guidance about carotenoid supplementation in hypobetalipoproteinemias. • Carotenoid absorption is impaired in cells mimicking patient enterocytes. • Carotenoid plasma levels are dramatically low in patients compared to controls. • Evaluation of patient carotenoid status may help guide treatment. Familial hypobetalipoproteinemias (FHBL) are rare genetic diseases characterized by lipid malabsorption. We focused on abetalipoproteinemia (FHBL-SD1) and chylomicron retention disease (FHBL-SD3), caused by mutations in microsomal triglyceride transfer protein (MTTP) and SAR1B genes, respectively. Treatments include a low-fat diet and high-dose fat-soluble vitamin supplementations. However, patients are not supplemented in carotenoids, a group of lipid-soluble pigments essential for eye health. Our aim was to evaluate carotenoid absorption and status in the context of hypobetalipoproteinemia. We first used knock-out Caco-2/TC7 cell models of FHBL-SD1 and FHBL-SD3 to evaluate carotenoid absorption. We then characterized FHBL-SD1 and FHBL-SD3 patient status in the main dietary carotenoids and compared it to that of control subjects. In vitro results showed a significant decrease in basolateral secretion of α- and β-carotene, lutein, and zeaxanthin (-88.8 ± 2.2 % to -95.3 ± 5.8 %, -79.2 ± 4.4 % to -96.1 ± 2.6 %, -91.0 ± 4.5 % to -96.7 ± 0.3 % and -65.4 ± 3.6 % to -96.6 ± 1.9 %, respectively). Carotenoids plasma levels in patients confirmed significant deficiencies, with decreases ranging from –89 % for zeaxanthin to -98 % for α-carotene, compared to control subjects. Given the continuous loss in visual function despite fat-soluble vitamin treatment in some patients, carotenoid supplementation may be of clinical utility. Future studies should assess the correlation between carotenoid status and visual function in aging patients and investigate whether carotenoid supplementation could prevent their visual impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF